bLong Financial LLC Makes New $852,000 Investment in Johnson & Johnson (NYSE:JNJ)

bLong Financial LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,889 shares of the company's stock, valued at approximately $852,000. Johnson & Johnson comprises 0.7% of bLong Financial LLC's holdings, making the stock its 24th biggest position.

A number of other large investors have also added to or reduced their stakes in the business. AMF Tjanstepension AB raised its holdings in Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company's stock worth $68,985,000 after purchasing an additional 52,997 shares during the last quarter. Alpha Financial Partners LLC bought a new position in Johnson & Johnson during the 3rd quarter worth approximately $209,000. Wealth Group Ltd. bought a new position in Johnson & Johnson during the 3rd quarter worth approximately $213,000. Swedbank AB grew its position in shares of Johnson & Johnson by 5.3% during the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company's stock worth $358,980,000 after buying an additional 111,570 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Johnson & Johnson by 0.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 451,598 shares of the company's stock worth $73,186,000 after buying an additional 2,437 shares during the period. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Wells Fargo & Company reduced their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Bank of America reduced their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, January 23rd. Raymond James reduced their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Guggenheim lifted their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a "neutral" rating in a research report on Monday, February 3rd. Finally, Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $170.67.

Insider Activity

In related news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark A. Weinberger bought 1,000 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

JNJ traded up $2.67 during trading hours on Friday, hitting $162.35. The stock had a trading volume of 12,540,171 shares, compared to its average volume of 9,073,381. The company's fifty day simple moving average is $148.61 and its 200 day simple moving average is $155.89. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a market cap of $390.87 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company's quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.29 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.